Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Robert Wassman, Dganit Bar, David Suhy

Premium

Rosetta Genomics announced that it has named Robert Wassman as its new chief medical officer and Dganit Bar as its new chief scientific officer.

Wassman is a medical geneticist and has held various executive positions at companies including Genzyme Genetics. He most recently served as CMO at Generation Health.

Bar joins Rosetta from BioLineRx, where she served as executive director of science and technology. She also worked at QBI Enterprises, a subsidiary of Quark Pharmaceuticals.


Benitec Biopharma announced that Tacere Therapeutics' director of research and development, David Suhy, has been named its new senior vice president of research and development.

Suhy's appointment comes with Benitec's acquisition of Tacere.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.